Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate

Phase 1approvedAK158D1Positive

AI Analysis

Summary

Akeso's bispecific ADC candidate AK158D1 targeting EGFR and TROP2 has received Phase I clinical trial clearance from China's NMPA for advanced solid tumors, representing the company's fourth clinical-stage ADC candidate.

Clinical Trial Data

Phase

Phase 1

Outcome Details

NMPA Phase I clinical trial clearance granted

Importance:6/10

Sentiment:

0.80

ADCbispecific antibodyEGFRTROP2NMPA clearanceoncologyChina

Related Companies

$GBIO $SLDB

Read the original article

Published by PR Newswire Biotech on September 17, 2026 6:34 AM

Read Original